Novel Therapeutic Approach to Improve Hematopoiesis in low risk MDS by Targeting MDSCs with The Fc-engineered CD33 Antibody BI 836858

We recently reported that the accumulation of myeloid-derived suppressor cells (MDSC), defined as CD33(+)HLA-DR(−)Lin(−), plays a direct role in the pathogenesis of myelodysplastic syndrome (MDS). In particular, CD33 is strongly expressed in MDSC isolated from patients with MDS where it plays an imp...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Leukemia
Auteurs principaux: Eksioglu, Erika A., Chen, Xianghong, Heider, Karl-Heinz, Rueter, Bjoern, McGraw, Kathy L., Basiorka, Ashley A., Wei, Max, Burnette, Alexis, Cheng, Pinyang, Lancet, Jeffrey, Komrokji, Rami, Djeu, Julie, List, Alan, Wei, Sheng
Format: Artigo
Langue:Inglês
Publié: 2017
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5552472/
https://ncbi.nlm.nih.gov/pubmed/28096534
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2017.21
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires